Skip to main content

ERC

Publications

  • Participate
    • Patients
    • Doctors
    • Investors
  • Products
    • Gliovac/ERC1671
  • Media
    • News
    • Publications
  • About
    • Executive Management
    • Executive board
    • Scientific board
    • Milestone achievements
  • Contact

Error message

Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in _konnu_footer() (line 149 of /home/erc/web/erc-immunotherapy.com/public_html/sites/all/modules/konnu/konnu.module).
NewsPublications
Jul2022
Cohort Study of GLIOVAC/ERC1671/SITOIGANAP to treat Glioblastoma
Aug2018
Review - Therapeutic Immunization against Glioblastoma – Virgil Schijns
Aug2018
Phase II study of ERC1671/SITOIGANAP plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
Jan2018
Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat
Oct2015
Use of ERC-1671/SITOIGANAP Vaccine in a patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
May2015
Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat.
Apr2015
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined all- and auto-immune tumor reactivity.
Jul2012
Cancer Immunology.
May2012
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation
May2010
Immunotherapy of Malignant Gliomas using autologous and allogeneic tissue cells.

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Cookie and Privacy Policy for more details.
Close
Copyright © 2001-2025 ERC.SA. All rights reserved.
Made byKonnu
Cookie and Privacy PolicyTerms & Conditions
Top